Shopping Cart 0
Cart Subtotal
AED 0

Pituitary ACTH Hypersecretion (Cushing Disease)-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 7340

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 14680

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 22020
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Pituitary ACTH Hypersecretion (Cushing Disease)-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pituitary ACTH Hypersecretion (Cushing Disease)-Pipeline Review, H2 2017, provides an overview of the Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) pipeline landscape.

Cushing'sdisease is a condition which results from hypersecretion of adrenocorticotropic hormone (ACTH) due to pituitary gland tumor. Symptoms include acne or skin infections, backache, mental changes (such as depression, anxiety, or changes in behavior), plethora, menstrual disorders and weight gain. Treatment includes radiation, chemotherapy, and use of certain hormone-inhibiting drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pituitary ACTH Hypersecretion (Cushing Disease)-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Pituitary ACTH Hypersecretion (Cushing Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 2, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders).

The pipeline guide reviews pipeline therapeutics for Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it'smost promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Pituitary ACTH Hypersecretion (Cushing Disease)-Overview

Pituitary ACTH Hypersecretion (Cushing Disease)-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Pituitary ACTH Hypersecretion (Cushing Disease)-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Pituitary ACTH Hypersecretion (Cushing Disease)-Companies Involved in Therapeutics Development

Amryt Pharma plc

Crinetics Pharmaceuticals Inc

Cyclacel Pharmaceuticals Inc

Ipsen SA

Novartis AG

Strongbridge Biopharma plc

Pituitary ACTH Hypersecretion (Cushing Disease)-Drug Profiles

Antisense RNAi Oligonucleotide to Inhibit POMC for Cushing'sSyndrome and Cushing Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-102-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIM-23B065-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

levoketoconazole-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MPP-482-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

osilodrostat phosphate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pasireotide ER-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

seliciclib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Cushing Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

veldoreotide-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pituitary ACTH Hypersecretion (Cushing Disease)-Dormant Projects

Pituitary ACTH Hypersecretion (Cushing Disease)-Discontinued Products

Pituitary ACTH Hypersecretion (Cushing Disease)-Product Development Milestones

Featured News & Press Releases

Jul 02, 2015: First Patient Dosed in IST of CDK Inhibitor Seliciclib in Cushing's Disease, a Serious Endocrine Disorder

Feb 23, 2015: Cortendo to Join Patients, Families and Pennsylvania Legislators to Raise Awareness for Rare Diseases

Jan 29, 2015: COR-003 Phase 3 Study Protocol to be Presented at ENDO 2015: The Endocrine Society's97th Annual Meeting & Expo

Oct 03, 2014: Cortendo AB to Present at the 13th Annual BIO Investor Forum in San Francisco October 7, 2014

Sep 30, 2014: Cortendo AB to Present at the Epic Biotech Conference in London on October 2, 2014

Sep 29, 2014: Cortendo AB to Present at the 14th Annual BIOTECH in Europe Forum in Basel September 30, 2014

Aug 12, 2014: First Patient Enrolled into NormoCort Phase 3 SONICS Trial Following a Successful EU Investigator Meeting

Jul 09, 2014: CORTENDO Reports Continued Progress On Phase 3 SONICS Trial

Jul 30, 2012: Cortendo's NormoCort Receives Orphan Drug Designation From EMA To Treat Cushing'sSyndrome

Mar 15, 2012: Cortendo Receives FDA Orphan Drug Designation For NormoCort In Cushing'sSyndrome

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing Disease), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Top 10 Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing Disease), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pituitary ACTH Hypersecretion (Cushing Disease)-Pipeline by Amryt Pharma plc, H2 2017

Pituitary ACTH Hypersecretion (Cushing Disease)-Pipeline by Crinetics Pharmaceuticals Inc, H2 2017

Pituitary ACTH Hypersecretion (Cushing Disease)-Pipeline by Cyclacel Pharmaceuticals Inc, H2 2017

Pituitary ACTH Hypersecretion (Cushing Disease)-Pipeline by Ipsen SA, H2 2017

Pituitary ACTH Hypersecretion (Cushing Disease)-Pipeline by Novartis AG, H2 2017

Pituitary ACTH Hypersecretion (Cushing Disease)-Pipeline by Strongbridge Biopharma plc, H2 2017

Pituitary ACTH Hypersecretion (Cushing Disease)-Dormant Projects, H2 2017

Pituitary ACTH Hypersecretion (Cushing Disease)-Discontinued Products, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

Amryt Pharma plc

Crinetics Pharmaceuticals Inc

Cyclacel Pharmaceuticals Inc

Ipsen SA

Novartis AG

Strongbridge Biopharma plc

Pituitary ACTH Hypersecretion (Cushing Disease)-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pituitary ACTH Hypersecretion (Cushing Disease)-Pipeline Review, H2 2017, provides an overview of the Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) pipeline landscape.

Cushing'sdisease is a condition which results from hypersecretion of adrenocorticotropic hormone (ACTH) due to pituitary gland tumor. Symptoms include acne or skin infections, backache, mental changes (such as depression, anxiety, or changes in behavior), plethora, menstrual disorders and weight gain. Treatment includes radiation, chemotherapy, and use of certain hormone-inhibiting drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pituitary ACTH Hypersecretion (Cushing Disease)-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Pituitary ACTH Hypersecretion (Cushing Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 2, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders).

The pipeline guide reviews pipeline therapeutics for Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it'smost promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Pituitary ACTH Hypersecretion (Cushing Disease)-Overview

Pituitary ACTH Hypersecretion (Cushing Disease)-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Pituitary ACTH Hypersecretion (Cushing Disease)-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Pituitary ACTH Hypersecretion (Cushing Disease)-Companies Involved in Therapeutics Development

Amryt Pharma plc

Crinetics Pharmaceuticals Inc

Cyclacel Pharmaceuticals Inc

Ipsen SA

Novartis AG

Strongbridge Biopharma plc

Pituitary ACTH Hypersecretion (Cushing Disease)-Drug Profiles

Antisense RNAi Oligonucleotide to Inhibit POMC for Cushing'sSyndrome and Cushing Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-102-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIM-23B065-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

levoketoconazole-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MPP-482-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

osilodrostat phosphate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pasireotide ER-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

seliciclib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Cushing Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

veldoreotide-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pituitary ACTH Hypersecretion (Cushing Disease)-Dormant Projects

Pituitary ACTH Hypersecretion (Cushing Disease)-Discontinued Products

Pituitary ACTH Hypersecretion (Cushing Disease)-Product Development Milestones

Featured News & Press Releases

Jul 02, 2015: First Patient Dosed in IST of CDK Inhibitor Seliciclib in Cushing's Disease, a Serious Endocrine Disorder

Feb 23, 2015: Cortendo to Join Patients, Families and Pennsylvania Legislators to Raise Awareness for Rare Diseases

Jan 29, 2015: COR-003 Phase 3 Study Protocol to be Presented at ENDO 2015: The Endocrine Society's97th Annual Meeting & Expo

Oct 03, 2014: Cortendo AB to Present at the 13th Annual BIO Investor Forum in San Francisco October 7, 2014

Sep 30, 2014: Cortendo AB to Present at the Epic Biotech Conference in London on October 2, 2014

Sep 29, 2014: Cortendo AB to Present at the 14th Annual BIOTECH in Europe Forum in Basel September 30, 2014

Aug 12, 2014: First Patient Enrolled into NormoCort Phase 3 SONICS Trial Following a Successful EU Investigator Meeting

Jul 09, 2014: CORTENDO Reports Continued Progress On Phase 3 SONICS Trial

Jul 30, 2012: Cortendo's NormoCort Receives Orphan Drug Designation From EMA To Treat Cushing'sSyndrome

Mar 15, 2012: Cortendo Receives FDA Orphan Drug Designation For NormoCort In Cushing'sSyndrome

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing Disease), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Top 10 Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing Disease), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pituitary ACTH Hypersecretion (Cushing Disease)-Pipeline by Amryt Pharma plc, H2 2017

Pituitary ACTH Hypersecretion (Cushing Disease)-Pipeline by Crinetics Pharmaceuticals Inc, H2 2017

Pituitary ACTH Hypersecretion (Cushing Disease)-Pipeline by Cyclacel Pharmaceuticals Inc, H2 2017

Pituitary ACTH Hypersecretion (Cushing Disease)-Pipeline by Ipsen SA, H2 2017

Pituitary ACTH Hypersecretion (Cushing Disease)-Pipeline by Novartis AG, H2 2017

Pituitary ACTH Hypersecretion (Cushing Disease)-Pipeline by Strongbridge Biopharma plc, H2 2017

Pituitary ACTH Hypersecretion (Cushing Disease)-Dormant Projects, H2 2017

Pituitary ACTH Hypersecretion (Cushing Disease)-Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Companies

Amryt Pharma plc

Crinetics Pharmaceuticals Inc

Cyclacel Pharmaceuticals Inc

Ipsen SA

Novartis AG

Strongbridge Biopharma plc